Adeno-associated virus (AAV) vectors have become an attractive tool for efficient gene
transfer into animal tissues. Extensively studied as the vehicles for therapeutic constructs in …

Gene therapy is a novel method under investigation for the treatment of neurological
disorders. Considerable interest has focused on the possibility of using viral vectors to …

Several neurodevelopmental and neurodegenerative disorders affecting the central nervous
system are potentially treatable via viral vector-mediated gene transfer. Adeno-associated …

Adeno-associated virus (AAV) vectors have become an important tool for delivering
therapeutic genes for a wide range of neurological diseases. AAV serotypes possess …

Gene therapy is a promising approach for treating a spectrum of neurological and
neurodegenerative disorders by delivering corrective genes to the central nervous system …

Gene therapy approaches based on adeno-associated viral vector (AAV) systems offer
many unique advantages for nervous system applications. These vectors are opening up …

Adeno-associated viral (AAV) vectors have become the primary delivery agent for somatic
gene transfer into the central nervous system (CNS). To date, AAV-mediated gene delivery …

Canine models have many advantages for evaluating therapy of human central nervous
system (CNS) diseases. In contrast to nonhuman primate models, naturally occurring canine …

Adeno‐associated virus (AAV) vectors are able to transduce CNS cells in vitro and in vivo for
extended periods of time without immune complications. The ability to efficiently deliver …

Vectors based on adeno-associated virus (AAV) have recently been used in phase I clinical
trials for the treatment of neurological disorders, such as Parkinson's and Canavan's …